Home › Funds › Kintegral Advisory, LLC › GILD
Kintegral Advisory, LLC position in GILD
GILEAD SCIENCES INC · Health Care
Kintegral Advisory, LLC reported holding 115,751 shares of GILD (GILEAD SCIENCES INC) in its Q3 2026 13F filing — a position valued at US$17.3M, representing 1.36% of its reported portfolio and ranking #10 among its reported holdings. Kintegral Advisory, LLC has disclosed GILD holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-10-17 · Source: SEC EDGAR Form 13F-HR
How Kintegral Advisory, LLC's GILD position evolved
Kintegral Advisory, LLC first disclosed a stake in GILD in Q3 2023 at 81,527 shares (US$6.1M). The position peaked in Q3 2026 at 115,751 shares, worth US$17.3M. Across 13 filings, Kintegral Advisory, LLC increased the stake 2 time(s), trimmed it 5 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 115,751 shares valued at US$17.3M — an increase of 654 shares quarter over quarter.. Notable position changes include a 64% increase in Q2 2024 (shares rose 22% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 81.53K | $6.11M | New |
| Q4 2023 | 81.01K | $6.56M | Reduce |
| Q1 2024 | 80.76K | $5.92M | Hold |
| Q2 2024 | 132.16K | $9.07M | Add |
| Q3 2024 | 130.45K | $10.94M | Reduce |
| Q4 2024 | 124.65K | $11.51M | Reduce |
| Q1 2025 | 124.23K | $13.92M | Hold |
| Q2 2025 | 124.04K | $13.75M | Hold |
| Q3 2025 | 123.49K | $13.71M | Hold |
| Q4 2025 | 120.20K | $14.75M | Reduce |
| Q1 2026 | 115.10K | $16.04M | Reduce |
| Q2 2026 | 115.10K | $14.54M | Hold |
| Q3 2026 | 115.75K | $17.25M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GILD and 13F data
GILD (GILEAD SCIENCES INC) is a Health Care company. 35 other funds we track also report a position in GILD — the largest reported positions include Fidelity Management & Research (FMR) (US$8.45B), Capital World Investors (US$5.18B), Capital World Investors (US$5.18B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GILD
- Fidelity Management & Research (FMR) 66.87M sh · $8.45B · Q2 2026
- Capital World Investors 40.99M sh · $5.18B · Q2 2026
- Capital World Investors 40.99M sh · $5.18B · Q2 2026
- Invesco Ltd 39.82M sh · $5.03B · Q2 2026
- PRICE T ROWE ASSOCIATES INC /MD/ 30.00M sh · $3.79B · Q2 2026
- Dodge & Cox 23.68M sh · $2.99B · Q2 2026
- DODGE & COX 23.68M sh · $2.99B · Q2 2026
More on Kintegral Advisory, LLC
FAQ
How long has Kintegral Advisory, LLC held GILD?
Kintegral Advisory, LLC has disclosed GILD holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Kintegral Advisory, LLC's current position in GILD?
As of Q3 2026, Kintegral Advisory, LLC holds 115.75K shares of GILD (GILEAD SCIENCES INC), valued at $17.25M, representing 1.36% of its reported portfolio and ranking #10.
Has Kintegral Advisory, LLC been buying or selling GILD?
In the latest 13F filing (Q3 2026), Kintegral Advisory, LLC increased its position in GILD. The position peaked in Q3 2026 at 115.75K shares.
Which other funds hold GILD?
Other major institutional holders of GILD include Fidelity Management & Research (FMR), Capital World Investors, Capital World Investors, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.